Geopolitical crises are taking a toll on stocks as we head into the seasonally weak month of August.
VIDEO ON MSN MONEY
A string of better-than-expected quarters suggests a turnaround is developing for the retailer.
There’s a nice turnaround story building at Foot Locker (FL), the specialty athletic retailer that operates approximately 3,400 stores in 22 countries.
Solid operating momentum, a cash-heavy balance sheet, and an attractive yield of nearly 3% are just a few of the attractions of these shares.
Its best-selling drug ever goes off patent. What's next for the world's largest drug company?
The day finally came when the world's largest drug company, Pfizer (PFE), lost patent protection on the best selling drug ever, cholesterol fighter Lipitor.
Lipitor has been a major source of income for the New York-based pharmaceutical. The pill was released in 1997, and by 2006 it had reached peak sales of $12.9 billion, accounting for 27% of the company's revenue. Even after Pfizer acquired Wyeth, Lipitor still accounted for 15.8% of total revenue in 2010, with $10.8 billion in sales. Altogether, Lipitor sales surpassed $100 billion.
Despite economic uncertainty, people have continued to eat out. We've found 5 restaurant stocks that offer both fundamental and technical strength. Pizza chains are stand-outs.
By Kate Stalter, MoneyShow.com
Consumers and businesses have continued going out to restaurants and spending money, even in a shaky economy. While many stocks have been struggling below key moving averages in the recent market volatility, several restaurants are trading at or near all-time highs.
Pizza restaurants, in particular, are standouts, with a few chains delivering fresh price action that’s far outpacing the broader market.
So far, betting on upscale retailers has proved to be a wise strategy, but a disappointing forecast from Tiffany's could mean future growth will be harder to find.
By Suzanne McGee, The Fiscal Times
Tiffany's (TIF) earnings may look glittery on the surface, with the jeweler on Tuesday reporting a 63% jump in its third-quarter results and boosting its forecast for the year by another nickel a share to as much as $3.80. But even the news that Tiffany's same-store sales climbed by 16% (excluding currency fluctuations) in the third quarter – at a time when other retailers have a tough time topping 4% or 5% – wasn't enough to allow the stock to shine. Even as the broader market rallied strongly Wednesday, Tiffany’s shares edged lower, following a drop of almost 9% the day before.
Sales growth at Tiffany’s seems to be slowing, and the fourth quarter will be a slower one than the company expected. Investors also were unnerved by the company's news that gross margins narrowed, in large part due to the fact that sales were of more costly items, which usually have lower margins.
As jobs come back, so will homebuyers.
Has housing bottomed? Did we finally get a number Wednesday that shows it is bottoming? Possibly, but it wasn't the pending home sales figure. Although they jumped 10.4%, that isn't how housing will trough.
It will be based on employment, and the numbers from ADP said the U.S. added 206,000 jobs in November. That's much better than the expected 130,000, and it may be the key number to focus on if we are to believe that housing can stop going down.
The master limited partnerships provide high income as well as growth leveraged to the energy sector.
The case for commodities is clear, but so is the case for income. What better way to kill two birds with one stone than to invest in income plays leveraged to commodities.
Here are two of our favorites -- master limited partnerships in the energy area poised to capitalize on high oil prices.
Master limited partnerships (MLPs) are required to distribute the bulk of their cash flow to stockholders.
Superstar collections fail to bring in the crowds as the deparment store continues to struggle.
Kim Kardashian became a world sensation almost overnight. The celebrity has her own reality show and millions of fans. So you would think the fashionably chic Kardashian Kollection would have been besieged by shoppers and sold out during the Black Friday rush. After all, practically all major retail stores, including Macy’s (M) and Target (TGT), were swamped by tens of thousands of eager shoppers.
But that wasn't the case at Sears (SHLD), where the Kardashian Kollection held sway and was among the elegant products displayed for sale. In fact, Sears was betting the Kardashian name and collection of fashion products would stir up consumer excitement.
Privatization is a growing trend in the water sector; here's how to play this theme.
As budget-strapped municipalities seek funding to clean up their decaying water and wastewater systems, privatization is a word that keeps popping up.
With the EPA estimating that it will cost more than $1 trillion over the next 20 years to maintain the current water infrastructure system, privatizing the systems may be an attractive solution.
The glass maker recently increased its dividend by 50% -- a sign it expects long-term improvement in its business.
Builders get upgraded at Raymond James, as do several energy stocks at Barclays.
- Anadarko (APC) upgraded to Overweight from Equal Weight at Barclays
- Nexen (NXY) upgraded to Overweight from Equal Weight at Barclays
- Cenovus Energy (CVE) upgraded to Overweight from Equal Weight at Barclays
- Transocean (RIG) upgraded to Hold from Trim at Tudor Pickering
- Navistar (NAV) upgraded to Neutral from Sell at Goldman
- Toll Brothers (TOL) upgraded to Outperform from Market Perform at Raymond James
- D.R. Horton (DHI) upgraded to Outperform from Market Perform at Raymond James
- Lennar (LEN) upgraded to Outperform from Market Perform at Raymond James
The tobacco company expects significant market share gains in Japan, Indonesia, Philippines, South Korea and Vietnam.
PMI expects cigarette volume (outside the U.S.) to increase as much as 1.3% a year over the next five years -- an improved outlook compared with previous forecasts. Philip Morris International competes with British American Tobacco (BTI), Japan Tobacco and Imperial Tobacco Group (IMT) in its various geographical segments.
Investors are cheering a decision by the Federal Reserve to pump cheaper dollars into eurozone banks. Yet this merely treats a symptom, not the disease. And it won't save the euro.
All week, the U.S. stock market was curiously buoyant as the eurozone crisis deepened. Wednesday morning, we learned why: The Federal Reserve, in cooperation with major central banks around the world, reduced the cost of providing dollar liquidity to banks in need from 1% over the rate set in the market to 0.5% over.
This unleashed a surge of buying, short covering, and cheerfulness as initial scans of the headlines seemed to suggest the Fed was riding to Europe's rescue. Not quite.
The Fed is merely postponing the inevitable, treating a symptom (bank funding problem) not the disease (a solvency crisis amongst eurozone governments).
The stock is downgraded to 'underperform' by a prominent analyst who says the company is broken.
On a day when stocks soared, Netflix's (NFLX) drop was particularly jarring.
The stock just can't catch a break after passing $300 in July. Its plunge since then has been breathtaking, with shares closing at $64.53 Wednesday.
The day's fall was triggered largely by a downgrade from one of the more prominent analysts covering the stock. Michael Pachter of Wedbush Morgan said in a research note to investors that the company is broken.
Increasing competition in its core business has forced the company to offer value-add services to augment its product portfolio and protect margins.
Cotendo, a smaller Israeli rival which competes with Akamai for value-added services, was founded in 2008 and launched in March of last year. The company has raised more than $36 million in funding from Sequoia Capital, Benchmark Capital and other investors, and also has the backing of strategic partners such as Citrix, Juniper (JNPR), Google (GOOG) and AT&T (T).
But a few are more likely to sell than others. Here are some names.
By Brian Orelli
Another day, another buyout rumor. Monday, it was Onyx Pharmaceuticals (ONXX) that jumped after Bloomberg said the company was in the early stages of exploring the possibility of putting itself up for sale. Before that it wasAchillion Pharmaceuticals (ACHN). And BioSante Pharmaceuticals (BPAX) before that. The rumor list is a mile long.
Here's a news flash for you: Every public biotech could be sold at any point.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The high-definition camera maker gives its first earnings report as a public company Thursday afternoon.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The S&P 500 has inched up from its worst level of the session, but that could be overlooked considering the index remains lower by 28 points.
Today's retreat has sent the benchmark average below its 50-day moving average (1953) for the first time in a while. Specifically, the index tested, but never closed below the 50-day average on six occasions during a three-week stretch between late April and early May. Prior to that span, the S&P 500 dove below the 50-day ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|